Topiramate

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cocaine-Related Disorders

Conditions

Cocaine-Related Disorders

Trial Timeline

Jan 1, 2007 → Dec 1, 2010

NCT ID

NCT00223626

About Topiramate

Topiramate is a phase 2 stage product being developed by Johnson & Johnson for Cocaine-Related Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00223626. Target conditions include Cocaine-Related Disorders.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00223626	Phase 2	Completed	Jan 1, 2007	Dec 1, 2010	Cocaine-Related Disorders
NCT00266604	Approved	Completed	Dec 1, 2005	Jun 1, 2007	Epilepsy
NCT00223639	Phase 2	Completed	Sep 1, 2005	Jul 1, 2008	Alcoholism
NCT00233012	Phase 1	Completed	Jun 1, 2005	Oct 1, 2007	Seizures
NCT00210574	Phase 2	Completed	Mar 1, 2005	Oct 1, 2006	Epilepsy, Absence
NCT00210860	Phase 3	Completed	Sep 1, 2004	Mar 1, 2006	Migraine
NCT00210925	Phase 2	Completed	Mar 1, 2004	Aug 1, 2006	Alcoholism
NCT00231647	Phase 2	Completed	Feb 1, 2004	Oct 1, 2004	Obesity
NCT00210821	Phase 3	Completed	Feb 1, 2004	Nov 1, 2005	Migraine
NCT00210873	Phase 3	Completed	Feb 1, 2004	Aug 1, 2005	Migraine
NCT00210808	Phase 2/3	Completed	Sep 1, 2003	Mar 1, 2005	Obesity
NCT00210912	Phase 3	Completed	Sep 1, 2003	Apr 1, 2005	Migraine
NCT00236496	Phase 3	Completed	Oct 1, 2001	Feb 1, 2004	Essential Tremor
NCT00035230	Phase 3	Completed	Jul 1, 2001	Nov 1, 2002	Bipolar Disorder
NCT00231673	Phase 2	Completed	Jul 1, 2001	Jan 1, 2003	Diabetic Neuropathies
NCT00231634	Phase 3	Terminated	May 1, 2001	Nov 1, 2002	Obesity
NCT00231621	Phase 3	Terminated	May 1, 2001	Jun 1, 2002	Obesity
NCT00231595	Phase 3	Completed	Mar 1, 2001	Nov 1, 2002	Migraine
NCT00236665	Phase 3	Completed	Mar 1, 2001	Jun 1, 2002	Obesity
NCT00236509	Phase 3	Completed	Feb 1, 2001	Sep 1, 2002	Migraine

Competing Products

3 competing products in Cocaine-Related Disorders

See all competitors

Product	Company	Stage	Hype Score
Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral Therapy	Johnson & Johnson	Phase 3	77
quetiapine	AstraZeneca	Approved	85
AFQ056 + Placebo	Novartis	Phase 2	52

Other Products from Johnson & Johnson

Fentanyl transdermal therapeutic systemApproved

Nicotine Gum + Nicotine PatchApproved

galantamineApproved

IbrutinibApproved

Paliperidone ERApproved